Skip to main content

2021 | Bipolare affektive Störung | OriginalPaper | Buchkapitel

2. Medikamente zur Behandlung bipolarer Störungen

verfasst von : PD Dr. med. Michael Paulzen, Prof. Dr. med. Gerhard Gründer, Otto Benkert

Erschienen in: Kompendium der Psychiatrischen Pharmakotherapie

Verlag: Springer Berlin Heidelberg

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Stimmungsstabilisierer im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben. Ein Schwerpunkt liegt in der Darstellung des Risikos der Antidepressiva bei der Verordnung bei der bipolaren Depression.
Literatur
Zurück zum Zitat Amsterdam JD, Lorenzo-Luaces L, Soeller I et al (2015) Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: a randomized, double-blind, parallel-group, prospective study. J Affect Disord 185:31–37 CrossRef Amsterdam JD, Lorenzo-Luaces L, Soeller I et al (2015) Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: a randomized, double-blind, parallel-group, prospective study. J Affect Disord 185:31–37 CrossRef
Zurück zum Zitat Berk M, Daglas R, Dandash O et al (2017) Quetiapine v. lithium in the maintenance phase following a first episode of mania: randomised controlled trial. Br J Psychiatry 210(6):413–421 CrossRef Berk M, Daglas R, Dandash O et al (2017) Quetiapine v. lithium in the maintenance phase following a first episode of mania: randomised controlled trial. Br J Psychiatry 210(6):413–421 CrossRef
Zurück zum Zitat Berk M, Turner A, Malhi G et al (2019) A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. BMC Med 17(1):18 CrossRef Berk M, Turner A, Malhi G et al (2019) A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. BMC Med 17(1):18 CrossRef
Zurück zum Zitat Chang HY, Tseng PT, Stubbs B et al (2017) The efficacy and tolerability of paliperidone in mania of bipolar disorder: a preliminary meta-analysis. Exp Clin Psychopharmacol 25(5):422–433 CrossRef Chang HY, Tseng PT, Stubbs B et al (2017) The efficacy and tolerability of paliperidone in mania of bipolar disorder: a preliminary meta-analysis. Exp Clin Psychopharmacol 25(5):422–433 CrossRef
Zurück zum Zitat Chen TY, Kamali M, Chu CS et al (2019) Divalproex and its effect on suicide risk in bipolar disorder: a systematic review and meta-analysis of multinational observational studies. J Affect Disord 245:812–818 CrossRef Chen TY, Kamali M, Chu CS et al (2019) Divalproex and its effect on suicide risk in bipolar disorder: a systematic review and meta-analysis of multinational observational studies. J Affect Disord 245:812–818 CrossRef
Zurück zum Zitat Cheniaux E, Nardi AE (2019) Evaluating the efficacy and safety of antidepressants in patients with bipolar disorder. Expert Opin Drug Saf 18(10):893–913 CrossRef Cheniaux E, Nardi AE (2019) Evaluating the efficacy and safety of antidepressants in patients with bipolar disorder. Expert Opin Drug Saf 18(10):893–913 CrossRef
Zurück zum Zitat Geddes JR, Gardiner A, Rendell J et al (2016) Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial. Lancet Psychiatry 3(1):31–39 CrossRef Geddes JR, Gardiner A, Rendell J et al (2016) Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial. Lancet Psychiatry 3(1):31–39 CrossRef
Zurück zum Zitat Grover S, Kukreti R (2014) HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis. Pharmacogenet Genomics 24(2):94–112 CrossRef Grover S, Kukreti R (2014) HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis. Pharmacogenet Genomics 24(2):94–112 CrossRef
Zurück zum Zitat Grunze H, Vieta E, Goodwin GM et al (2018) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: acute and long-term treatment of mixed states in bipolar disorder. World J Biol Psychiatry 19(1):2–58 CrossRef Grunze H, Vieta E, Goodwin GM et al (2018) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: acute and long-term treatment of mixed states in bipolar disorder. World J Biol Psychiatry 19(1):2–58 CrossRef
Zurück zum Zitat Hiemke C, Bergemann N, Clement HW et al (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51(1-02):9–62 PubMed Hiemke C, Bergemann N, Clement HW et al (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51(1-02):9–62 PubMed
Zurück zum Zitat Hou L, Heilbronner U, Degenhardt F et al (2016) Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet 387(10023):1085–1093 CrossRef Hou L, Heilbronner U, Degenhardt F et al (2016) Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet 387(10023):1085–1093 CrossRef
Zurück zum Zitat Huang RY, Hsieh KP, Huang WW et al (2016) Use of lithium and cancer risk in patients with bipolar disorder: population-based cohort study. Br J Psychiatry 209(5):393–399 CrossRef Huang RY, Hsieh KP, Huang WW et al (2016) Use of lithium and cancer risk in patients with bipolar disorder: population-based cohort study. Br J Psychiatry 209(5):393–399 CrossRef
Zurück zum Zitat Joas E, Karanti A, Song J (2017) Pharmacological treatment and risk of psychiatric hospital admission in bipolar disorder. Br J Psychiatry 210(3):197–202 CrossRef Joas E, Karanti A, Song J (2017) Pharmacological treatment and risk of psychiatric hospital admission in bipolar disorder. Br J Psychiatry 210(3):197–202 CrossRef
Zurück zum Zitat Kessing LV, Gerds TA, Feldt-Rasmussen B et al (2015) Lithium and renal and upper urinary tract tumors – results from a nationwide population-based study. Bipolar Disord 17(8):805–813 CrossRef Kessing LV, Gerds TA, Feldt-Rasmussen B et al (2015) Lithium and renal and upper urinary tract tumors – results from a nationwide population-based study. Bipolar Disord 17(8):805–813 CrossRef
Zurück zum Zitat Kessing LV, Gerds TA, Knudsen NN et al (2017) Association of lithium in drinking water with the incidence of dementia. JAMA Psychiatry 74(10):1005–1010 CrossRef Kessing LV, Gerds TA, Knudsen NN et al (2017) Association of lithium in drinking water with the incidence of dementia. JAMA Psychiatry 74(10):1005–1010 CrossRef
Zurück zum Zitat Kessing LV, Bauer M, Nolen WA et al (2018) Effectiveness of maintenance therapy of lithium vs other mood stabilizers in monotherapy and in combinations: a systematic review of evidence from observational studies. Bipolar Disord. Online ahead of print Kessing LV, Bauer M, Nolen WA et al (2018) Effectiveness of maintenance therapy of lithium vs other mood stabilizers in monotherapy and in combinations: a systematic review of evidence from observational studies. Bipolar Disord. Online ahead of print
Zurück zum Zitat Ketter TA, Miller S, Dell’Osso B, Wang PW (2016) Treatment of bipolar disorder: review of evidence regarding quetiapine and lithium. J Affect Disord 191:256–273 CrossRef Ketter TA, Miller S, Dell’Osso B, Wang PW (2016) Treatment of bipolar disorder: review of evidence regarding quetiapine and lithium. J Affect Disord 191:256–273 CrossRef
Zurück zum Zitat Lähteenvuo M, Tanskanen A, Hoti F et al (2017) Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study. Lancet Psychiatry 4(7):547–553 CrossRef Lähteenvuo M, Tanskanen A, Hoti F et al (2017) Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study. Lancet Psychiatry 4(7):547–553 CrossRef
Zurück zum Zitat Lähteenvuo M, Tanskanen A, Taipale H et al (2018) Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder. Jama Psychiatry 75(4):347–355 CrossRef Lähteenvuo M, Tanskanen A, Taipale H et al (2018) Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder. Jama Psychiatry 75(4):347–355 CrossRef
Zurück zum Zitat Lorenzo-Luaces L, Amsterdam JD, Soeller I, DeRubeis RJ (2016) Rapid versus non-rapid cycling bipolar II depression: response to venlafaxine and lithium and hypomanic risk. Acta Psychiatr Scand 133(6):459–469 CrossRef Lorenzo-Luaces L, Amsterdam JD, Soeller I, DeRubeis RJ (2016) Rapid versus non-rapid cycling bipolar II depression: response to venlafaxine and lithium and hypomanic risk. Acta Psychiatr Scand 133(6):459–469 CrossRef
Zurück zum Zitat Melhuish Beaupre LM, Tiwari KA, Gonçalves VF et al (2020) Antidepressant-associated mania in bipolar disorder: a review and meta-analysis of potential clinical and genetic risk factors. J Clin Psychopharmacol 40(2):180–185 CrossRef Melhuish Beaupre LM, Tiwari KA, Gonçalves VF et al (2020) Antidepressant-associated mania in bipolar disorder: a review and meta-analysis of potential clinical and genetic risk factors. J Clin Psychopharmacol 40(2):180–185 CrossRef
Zurück zum Zitat Miura T, Noma H, Furukawa TA et al (2014) Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry 1(5):351–359 CrossRef Miura T, Noma H, Furukawa TA et al (2014) Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry 1(5):351–359 CrossRef
Zurück zum Zitat Owens DC (2019) Sodium valproate in psychiatric practice: time for a change in perception. Br J Psychiatry 13:1–3 Owens DC (2019) Sodium valproate in psychiatric practice: time for a change in perception. Br J Psychiatry 13:1–3
Zurück zum Zitat Pereira C, Chavarria V, Vian J et al (2018) Mitochondrial agents for bipolar disorder. Int J Neuropsychopharmacol 21(6):550–569 CrossRef Pereira C, Chavarria V, Vian J et al (2018) Mitochondrial agents for bipolar disorder. Int J Neuropsychopharmacol 21(6):550–569 CrossRef
Zurück zum Zitat Rosenblat JD (2019) Targeting the immune system in the treatment of bipolar disorder. Psychopharmacology 236:2909–2921 CrossRef Rosenblat JD (2019) Targeting the immune system in the treatment of bipolar disorder. Psychopharmacology 236:2909–2921 CrossRef
Zurück zum Zitat Saraf G, Moazen-Zadeh E, Pinto JV et al (2020) Early intervention for people at high risk of developing bipolar disorder: a systematic review of clinical trials. Lancet Psychiatry. Online ahead of print Saraf G, Moazen-Zadeh E, Pinto JV et al (2020) Early intervention for people at high risk of developing bipolar disorder: a systematic review of clinical trials. Lancet Psychiatry. Online ahead of print
Zurück zum Zitat Shine B, McKnight RF, Leaver L, Geddes JR (2015) Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet 386(9992):461–468 CrossRef Shine B, McKnight RF, Leaver L, Geddes JR (2015) Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet 386(9992):461–468 CrossRef
Zurück zum Zitat Smith KA, Cipriani A (2017) Lithium and suicide in mood disorders: updated meta-review of the scientific literature. Bipolar Disord 19(7):575–586 CrossRef Smith KA, Cipriani A (2017) Lithium and suicide in mood disorders: updated meta-review of the scientific literature. Bipolar Disord 19(7):575–586 CrossRef
Zurück zum Zitat Szegedi A, Durgam S, Mackle M et al (2018) Randomized, double-blind, placebo-controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar I disorder. Am J Psychiatry 175(1):71–79 CrossRef Szegedi A, Durgam S, Mackle M et al (2018) Randomized, double-blind, placebo-controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar I disorder. Am J Psychiatry 175(1):71–79 CrossRef
Zurück zum Zitat Szmulewicz AG, Angriman F, Samamé C (2017) Dopaminergic agents in the treatment of bipolar depression: a systematic review and meta-analysis. Acta Psychiatr Scand 135(6):527–538 CrossRef Szmulewicz AG, Angriman F, Samamé C (2017) Dopaminergic agents in the treatment of bipolar depression: a systematic review and meta-analysis. Acta Psychiatr Scand 135(6):527–538 CrossRef
Zurück zum Zitat Viktorin A, Rydén E, Thase ME et al (2017) The risk of treatment-emergent mania with methylphenidate in bipolar disorder. Am J Psychiatry 174(4):341–348 CrossRef Viktorin A, Rydén E, Thase ME et al (2017) The risk of treatment-emergent mania with methylphenidate in bipolar disorder. Am J Psychiatry 174(4):341–348 CrossRef
Zurück zum Zitat Vöhringer PA, Ostacher MJ, El-Mallakh RS et al (2015) Antidepressants in type II versus type I bipolar depression: a randomized discontinuation trial. J Clin Psychopharmacol 35(5):605–508 CrossRef Vöhringer PA, Ostacher MJ, El-Mallakh RS et al (2015) Antidepressants in type II versus type I bipolar depression: a randomized discontinuation trial. J Clin Psychopharmacol 35(5):605–508 CrossRef
Zurück zum Zitat Yatham LN, Kennedy SH, Parikh SV et al (2018) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 20(2):97–170 CrossRef Yatham LN, Kennedy SH, Parikh SV et al (2018) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 20(2):97–170 CrossRef
Zurück zum Zitat Young RC, Mulsant BH, Sajatovic M et al (2017) GERI-BD: a randomized double-blind controlled trial of lithium and divalproex in the treatment of mania in older patients with bipolar disorder. Am J Psychiatry 174(11):1086–1093 CrossRef Young RC, Mulsant BH, Sajatovic M et al (2017) GERI-BD: a randomized double-blind controlled trial of lithium and divalproex in the treatment of mania in older patients with bipolar disorder. Am J Psychiatry 174(11):1086–1093 CrossRef
Metadaten
Titel
Medikamente zur Behandlung bipolarer Störungen
verfasst von
PD Dr. med. Michael Paulzen
Prof. Dr. med. Gerhard Gründer
Otto Benkert
Copyright-Jahr
2021
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-662-61753-3_2

Passend zum Thema

ANZEIGE

Mittelgradige Depressionen & Johanniskraut: Das hat sich geändert

Die Behandlungsempfehlungen bei mittelgradiger Depression wurden erneuert und der Einsatz von Johanniskraut entscheidend präzisiert – welche zwei Empfehlungen Sie aus der aktualisierten Depressions-Leitlinie jetzt kennen sollten.

ANZEIGE

3 Kernaussagen: Cochrane-Analyse untersucht Johanniskrautextrakte

Johanniskraut gehört zu den am besten untersuchten pflanzlichen Arzneimitteln. Die Ergebnisse zur Wirksamkeit bei Depressionen wurden u. a. in einem Cochrane-Review analysiert [1]. Wie das pflanzliche Antidepressivum dabei abschnitt und welche drei Kernaussagen Sie für die Praxis kennen sollten, lesen Sie hier.

ANZEIGE

Depression behandeln. Natürlich.

Content Hub

Aktuelle Ergebnisse aus in-vitro- und in-vivo-Untersuchungen liefern detaillierte Erklärungen zum Wirkmechanismus von hochdosiertem Johanniskraut-Extrakt: Neu ist die Erkenntnis, dass der Johanniskraut-Extrakt bei chronischem Stress die deregulierte Stressantwort der überaktiven HPA-Achse sowie die Expression des Stressgens FKBP5 normalisieren kann. Mehr zum aktuellen Stand der Wissenschaft bei der Therapie von Depressionen erfahren Sie hier.